These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35902413)
21. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Forteza A; Evangelista A; Sánchez V; Teixidó-Turà G; Sanz P; Gutiérrez L; Gracia T; Centeno J; Rodríguez-Palomares J; Rufilanchas JJ; Cortina J; Ferreira-González I; García-Dorado D Eur Heart J; 2016 Mar; 37(12):978-85. PubMed ID: 26518245 [TBL] [Abstract][Full Text] [Related]
23. Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study. Bitar S; Thilly N; Agrinier N Eur J Clin Pharmacol; 2021 Oct; 77(10):1569-1581. PubMed ID: 33970296 [TBL] [Abstract][Full Text] [Related]
24. Atenolol versus Losartan in Marfan's Syndrome. Mallat Z; Tedgui A N Engl J Med; 2015 Mar; 372(10):980. PubMed ID: 25738683 [No Abstract] [Full Text] [Related]
25. Atenolol versus Losartan in Marfan's Syndrome. Lacro RV; Dietz HC; Mahony L N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680 [No Abstract] [Full Text] [Related]
26. Atenolol versus Losartan in Marfan's Syndrome. Treasure T; Pepper J; Mohiaddin R N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682 [No Abstract] [Full Text] [Related]
27. Atenolol versus Losartan in Marfan's Syndrome. Ziganshin BA; Mukherjee SK; Elefteriades JA N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681 [No Abstract] [Full Text] [Related]
28. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842 [TBL] [Abstract][Full Text] [Related]
29. The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers. Möberg K; De Nobele S; Devos D; Goetghebeur E; Segers P; Trachet B; Vervaet C; Renard M; Coucke P; Loeys B; De Paepe A; De Backer J Int J Cardiol; 2012 Jun; 157(3):354-8. PubMed ID: 21239069 [TBL] [Abstract][Full Text] [Related]
30. Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome. Hoskoppal A; Menon S; Trachtenberg F; Burns KM; De Backer J; Gelb BD; Gleason M; James J; Lai WW; Liou A; Mahony L; Olson AK; Pyeritz RE; Sharkey AM; Stylianou M; Wechsler SB; Young L; Levine JC; Tierney ESS; Lacro RV; Bradley TJ; Pediatr Cardiol; 2018 Oct; 39(7):1453-1461. PubMed ID: 29948025 [TBL] [Abstract][Full Text] [Related]
31. Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al. O'Rourke MF; Adji A; Weber T Vasc Med; 2016 Feb; 21(1):70. PubMed ID: 26669325 [No Abstract] [Full Text] [Related]
32. Racial and ethnic differences in response to treatment for Marfan syndrome. Ayers R; Kelleman M; Iannucci G; McCracken C; Oster ME Cardiol Young; 2021 Dec; 31(12):1991-1998. PubMed ID: 33845931 [TBL] [Abstract][Full Text] [Related]
33. [Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan]. Mariucci E; Guidarini M; Donti A; Lovato L; Wischmeijer A; Angeli E; Gargiulo GD; Picchio FM; Bonvicini M G Ital Cardiol (Rome); 2015 Dec; 16(12):690-5. PubMed ID: 26667946 [TBL] [Abstract][Full Text] [Related]
34. Of Marfan's syndrome, mice, and medications. Bowen JM; Connolly HM N Engl J Med; 2014 Nov; 371(22):2127-8. PubMed ID: 25405389 [No Abstract] [Full Text] [Related]
35. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Yetman AT; Bornemeier RA; McCrindle BW Am J Cardiol; 2005 May; 95(9):1125-7. PubMed ID: 15842990 [TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia. Kim HS; Kim H; Lee SH; Kim JH J Clin Pharm Ther; 2020 Dec; 45(6):1264-1270. PubMed ID: 32737930 [TBL] [Abstract][Full Text] [Related]
37. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN. Mayyas F; Bataineh W; Jarab A Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537 [TBL] [Abstract][Full Text] [Related]
38. Variability of discharge medical therapy for secondary prevention among patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) in the United States. Smilowitz NR; Dubner R; Hellkamp AS; Widmer RJ; Reynolds HR PLoS One; 2021; 16(8):e0255462. PubMed ID: 34339469 [TBL] [Abstract][Full Text] [Related]
39. Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. Schupp T; Behnes M; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Ansari U; El-Battrawy I; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I Cardiovasc Drugs Ther; 2018 Aug; 32(4):353-363. PubMed ID: 30074111 [TBL] [Abstract][Full Text] [Related]
40. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial. van Andel MM; Indrakusuma R; Jalalzadeh H; Balm R; Timmermans J; Scholte AJ; van den Berg MP; Zwinderman AH; Mulder BJM; de Waard V; Groenink M Eur Heart J; 2020 Nov; 41(43):4181-4187. PubMed ID: 32548624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]